The recent publicity could allow the company to get a good deal on Kenvue, which makes Tylenol, Band-Aids, and other ...

Kimberly-Clark is acquiring Tylenol maker Kenvue in a $48.7 billion cash-and-stock deal, creating a major consumer health goods company if shareholders approve.

IP, M&A, life sciences and competition partners advised on deal that brings together brands such as ‘Huggies’ and ‘Kleenex’ ...

A price-sensitive, value-conscious consumer adds a degree of unevenness and uncertainty to a robust earnings season.

CEO Alex Karp used the company's earnings call to dismiss his critics, saying, "Enjoy, get some popcorn, they're crying." ...

Kimberly-Clark plans to acquire Kenvue in a $48.7 billion deal, aiming to boost long-term growth and synergies. Learn more ...

It pays a semiannual dividend and yields 4.4% based on the two most recent payments. Morningstar Equity analysts note that ...

Kimberly-Clark, the maker of Huggies, said Monday it will acquire Kenvue, Tylenol’s parent, in a cash-and-stock transaction valued at nearly $50 billion. The companies said the combined portfolio will ...

While the canard that many mergers fail to provide a return to shareholders does not appear to be supported by the data, mergers still occur that appear to be motivated by little more than a CEO& ...

One of the biggest mergers of the year, worth $49 billion, comes just weeks after the Trump administration linked the common ...